( Posted by- Desinie Smith )
Multiple sclerosis (MS) patients who had undergone treatment with Betaferon since early diagnosis are living longer, healthier lives than those who waited until the disease progressed further, according to new data presented at a symposium in Melbourne on the weekend.
International MS expert Dr Thomas Leist, director of the Multiple Sclerosis Centre at Thomas Jefferson University in the US, presented a study on regular users of Betaferon (interferon beta-1b) which found that 84.7 per cent of patients on standard-dose treatment were still alive compared to 72.4 per cent of those on a placebo.